Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia

Assessment of measurable residual disease (MRD) provides prognostic information in acute myeloid leukemia (AML). However, the utility of MRD with venetoclax-based lower intensity regimens is unknown. We analyzed the prognostic value of achieving a negative MRD in older/“unfit” patients with AML rece...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood Adv
Hauptverfasser: Maiti, Abhishek, DiNardo, Courtney D., Wang, Sa A., Jorgensen, Jeffrey, Kadia, Tapan M., Daver, Naval G., Short, Nicholas J., Yilmaz, Musa, Pemmaraju, Naveen, Borthakur, Gautam, Bose, Prithviraj, Issa, Ghayas C., Ferrajoli, Alessandra, Jabbour, Elias J., Jain, Nitin, Garcia-Manero, Guillermo, Ohanian, Maro, Takahashi, Koichi, Montalban-Bravo, Guillermo, Masarova, Lucia, Burger, Jan A., Thompson, Philip A., Verstovsek, Srdan, Sasaki, Koji, Andreeff, Michael, Rausch, Caitlin R., Montalbano, Kathryn S., Pierce, Sherry, Qiao, Wei, Ning, Jing, Kantarjian, Hagop M., Konopleva, Marina Y., Ravandi, Farhad
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Hematology 2021
Schlagworte:
Clinical Trials and Observations
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8045494/
https://ncbi.nlm.nih.gov/pubmed/33792630
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020003717
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge